| |
All severe adverse events (N = 88)†
|
Severe hepatotoxicity(N = 10)
|
ZDV-related severe averse events (N = 71)
|
|---|
| |
HR
|
95% CI
|
p
|
HR
|
95% CI
|
p
|
HR
|
95% CI
|
p
|
|---|
|
Age (years)
| | | | | | | | | |
|
≥30 (n = 137)
|
1.03
|
0.67-1.59
|
0.90
|
1.37
|
0.37-5.06
|
0.64
|
0.92
|
0.57-1.49
|
0.74
|
|
<30 (n = 153)
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
|
Body mass index (Kg/m
2
)
| | | | | | | | | |
|
<18 (n = 40)
|
1.08
|
0.53-2.20
|
0.05
| | | |
1.12
|
0.52-2.42
|
0.78
|
|
≥18 (n = 160)
|
1.00
|
-
|
-
| | | |
1.00
|
-
|
-
|
|
CD4+ count/mm
3
| | | | | | | | | |
|
>250 (n = 88)
|
0.68
|
0.41-1.12
|
0.14
|
1.75
|
0.48-6.39
|
0.40
|
0.64
|
0.36-1.14
|
0.13
|
|
≤250 (n = 202)
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
|
WHO staging
| | | | | | | | | |
|
Stage 3 or 4 (n = 130)
|
1.00
|
0.63-1.58
|
0.99
|
1.31
|
0.36-4.74
|
0.68
|
1.07
|
0.65-1.79
|
0.77
|
|
Stage 1 or 2 (n = 160)
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
|
ALT (IU/L)
| | | | | | | | | |
|
≥31(n = 50)
|
1.58
|
0.89-2.78
|
0.12
|
7.09
|
1.59-31.62
|
0.01
|
1.10
|
0.57-2.15
|
0.78
|
|
<31(n = 240)
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
|
Neutrophil level (/mm
3
)
| | | | | | | | | |
|
<1500 (n = 28)
|
1.51
|
0.76-2.98
|
0.24
| | | |
2.20
|
1.09-4.43
|
0.03
|
|
≥1500 (n = 262)
|
1.00
|
-
|
-
| | | |
1.00
|
-
|
-
|
|
Hemoglobin level (g/dL)
| | | | | | | | | |
|
≤9.8 (n = 150)
|
1.15
|
0.73-1.82
|
0.56
|
0.66
|
0.16-2.79
|
0.57
|
1.35
|
0.81-2.23
|
0.25
|
|
>9.8 (n = 140)
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
|
Status of pregnancy
| | | | | | | | | |
|
Pregnant (n = 125)
|
0.98
|
0.60-1.64
|
0.98
|
1.22
|
0.22-6.62
|
0.82
|
1.11
|
0.65-1.91
|
0.70
|
|
Non pregnant (n = 165)
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
1.00
|
-
|
-
|
-
Multivariable Cox regression analyses. MTCT-Plus program, Abidjan, Côte d'Ivoire (2003-2006).
- HAART: Highly active antiretroviral therapy; WHO: World Health Organization; IQR: interquartile range; NVP: nevirapine; ALT: alanine aminotransferase; OR: odds ratio; aOR: adjusted odds ratio; CI: confidence interval, † If a woman had multiple severe adverse event
